FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

This is a Phase 1, uncontrolled, single-arm, open-label, nonrandomized, dose escalation, study of Decitabine (DAC)+Venetoclax (VEN)+FHD-286 in participants with newly diagnosed Acute Myeloid Leukemia (AML) classified as adverse risk per the 2022 European Leukemia Net (ELN) criteria or AML that has progressed after one prior line of therapy.

Trial Details

NCT ID
NCT07283094
Phase
PHASE1
Sponsor
Montefiore Medical Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Decitabine
  • Venetoclax
  • FHD-286
Locations (sample)
  • The Bronx, New York, United States|40.84985,-73.86641

Key Eligibility Criteria

  • Newly diagnosed adverse risk AML, including Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), per the 2022 ELN criteria, with a histopatho…
  • Inclusion Criteria 2 to 4 apply only for patients who are individuals with newly diagnosed AML:
  • Aged ≥75 years, or aged 18-74 years and either refuse to receive intensive induction chemotherapy or are not a candidate for intensive induction ch…
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 or 3

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →